Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
about
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSAA comparison of different antibiotic regimens for the treatment of infective endocarditisAntibiotics for bacteraemia due to Staphylococcus aureusAntibiotic therapy for treatment of infective endocarditisSystemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adultsCommunity-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsCombinatorial biosynthesis of novel antibiotics related to daptomycinBactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cellsDaptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsImproving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin AllergyProgress toward a Staphylococcus aureus vaccineCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciCyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteriaNovel formulations for antimicrobial peptidesEfficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trialsDaptomycin in paediatrics: current knowledge and the need for future researchMethicillin-resistant Staphylococcus aureus therapy: past, present, and futureTreatment of Gram-positive infections in critically ill patientsPotential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusNovel antibody-antibiotic conjugate eliminates intracellular S. aureusBacterial genome engineering and synthetic biology: combating pathogensWhole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureusManaging infective endocarditis in the elderly: new issues for an old disease.Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.Genotypically different clones of Staphylococcus aureus are diverse in the antimicrobial susceptibility patterns and biofilm formations.Management of community-associated methicillin-resistant Staphylococcus aureus infections in children.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report.A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.Incidence, risk factors and prediction of post-operative acute kidney injury following cardiac surgery for active infective endocarditis: an observational study.Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data.The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials.Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.A potential role for daptomycin in enterococcal infections: what is the evidence?Waves of resistance: Staphylococcus aureus in the antibiotic era.
P2860
Q22305769-9D3D5F3C-78B9-4979-91CF-F1E7439BC009Q24185887-23884EF8-DE7F-4E1E-947B-050AB1A7720FQ24186950-B7FF382F-A624-4844-A67D-F04FD727D206Q24198788-EA0B4C67-9E9E-46F8-AFD4-F869D665715BQ24242508-6E879582-B1F4-4501-A682-8AC98F6A252EQ24614464-CBED8D3D-5206-40BB-83D9-F1F2BB1EB3DFQ24646677-BD1B43BB-054F-4CC1-ABAE-237C3674345FQ24676630-2C511B00-F809-4DB5-8ED8-A8EA2E704AD7Q24682375-AEF55B2F-780D-4CC2-9FE9-33181A8C6186Q26752922-B4620EC8-2C54-4AEE-9DB4-B60A25EA1736Q26779453-2485C934-6D82-458D-9492-482D1D1AD912Q26829702-9786A960-A7A1-4264-AE69-2E597E87901AQ26853465-4987C917-916D-4C4C-BD07-510DD97E89A0Q26863225-B2C92FFA-8DEC-44C1-B4AF-02209DDEABDBQ26991771-97F397BE-36B1-4098-8F88-167142F895ACQ27000445-D68AF146-61C8-4213-B8B1-0E0EB7594417Q27006038-8D07B305-E876-42C3-B88C-961302D01D81Q27011165-A29C7E5D-6889-4B8F-B888-7132EA4A4191Q27015976-E93D3EC8-628F-4E36-9F69-D1E62F09A918Q27027412-CEB70F34-6C3F-49AE-999A-0FAAAC368868Q27702570-1F63D5C6-934A-4D4A-9EB1-41FCB5F68EF7Q28066540-D32C11EF-6CFD-4EC5-8183-46E5A0B5E902Q28740293-2CD6DEA1-9253-495B-B175-FD16471E426CQ30245399-8B9A3F15-3F4A-481F-B8C8-0DF076503661Q30449846-47B1F3D1-2AA3-44CC-B062-948D432272E1Q31148610-A36F91C9-B685-4013-88AE-C1DEE5BDFAD7Q33264579-7B22640E-AF00-4675-A3A3-97826A7F2364Q33429168-6E31D00D-16CA-4497-A03E-FAA31321B0BFQ33460707-DF130553-3344-416B-9F4B-BE6697411CD7Q33617737-1FF37852-8BF6-419A-996B-F45C03A97CD2Q33657212-2452FE20-88C8-4247-B7C3-82844A6E3FBEQ33718381-B9DE8723-E21B-4FCC-9D03-84BA1C6608B1Q33723124-8454D02A-3CE8-448D-9F16-93FBB37C6F19Q33752838-E40EF9A7-52FD-4901-9E64-2D6381BBA546Q33768851-45398EB4-6C44-4435-8179-5E55DBFBAD87Q33788313-FF4D0FE1-FAA5-4E50-BA50-207F7B125A94Q33834856-3F07E150-15E7-4BA2-9669-97640C3DC1B4Q33844670-27C3C2F0-E7EE-41A5-83BB-A444EAFE291FQ33845776-5E5F356C-9EBB-4D1D-94FD-C054204AAA91Q33854398-332017C4-0435-44DA-A78F-BAAD93076D32
P2860
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@ast
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@en
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@nl
type
label
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@ast
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@en
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@nl
prefLabel
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@ast
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@en
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@nl
P2093
P356
P1476
Daptomycin versus standard the ...... used by Staphylococcus aureus.
@en
P2093
Adolf W Karchmer
Arthur Stanley Link
Christopher H Cabell
Connie Savor Price
Donald P Levine
Elias Abrutyn
Francis P Tally
G Ralph Corey
Gloria A Vigliani
P304
P356
10.1056/NEJMOA053783
P407
P577
2006-08-01T00:00:00Z